Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 416475
                    [Title] => Heart specialists welcome ARB trial
                    [Summary] => Local heart specialists welcomed the results of a landmark trial showing that the angiotensin receptor blocker (ARB) telmisartan is as effective as, and better tolerated than, the gold standard angiotensin-converting enzyme (ACE) inhibitor ramipril in reducing the risk of heart attack, stroke and hospitalization for congestive heart failure in high-risk patients.
                    [DatePublished] => 2008-11-20 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 140669
                    [Title] => Cardiovascular study underway
                    [Summary] => The pharmaceutical company Boehringer Ingelheim has presented before the American Heart Association’s annual meeting its extensive cardiovascular trial program ONTARGET. 


The program will investigate the additional potential of newer blood pressure-reducing medications called angiotensin II receptor blocker such as telmisartan. 


Boehringer Ingelheim will also be conducting 10 additional cardiovascular studies. 


                    [DatePublished] => 2001-11-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 134000
                    [Title] => Study centers in 40 countries involved in heart pr
                    [Summary] => A total of 793 study centers in 40 countries have been recruited to enroll 28,400 patients over two years for the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) cardiovascular protection trial.


Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced this at the European Society of Cardiology Congress in Stockholm, Sweden.


                    [DatePublished] => 2001-09-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

ANGIOTENSIN

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 416475
                    [Title] => Heart specialists welcome ARB trial
                    [Summary] => Local heart specialists welcomed the results of a landmark trial showing that the angiotensin receptor blocker (ARB) telmisartan is as effective as, and better tolerated than, the gold standard angiotensin-converting enzyme (ACE) inhibitor ramipril in reducing the risk of heart attack, stroke and hospitalization for congestive heart failure in high-risk patients.
                    [DatePublished] => 2008-11-20 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 140669
                    [Title] => Cardiovascular study underway
                    [Summary] => The pharmaceutical company Boehringer Ingelheim has presented before the American Heart Association’s annual meeting its extensive cardiovascular trial program ONTARGET. 


The program will investigate the additional potential of newer blood pressure-reducing medications called angiotensin II receptor blocker such as telmisartan. 


Boehringer Ingelheim will also be conducting 10 additional cardiovascular studies. 


                    [DatePublished] => 2001-11-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 134000
                    [Title] => Study centers in 40 countries involved in heart pr
                    [Summary] => A total of 793 study centers in 40 countries have been recruited to enroll 28,400 patients over two years for the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) cardiovascular protection trial.


Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced this at the European Society of Cardiology Congress in Stockholm, Sweden.


                    [DatePublished] => 2001-09-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Heart specialists welcome ARB trial

November 20, 2008 - 12:00am

Local heart specialists welcomed the results of a landmark trial showing that the angiotensin receptor blocker (ARB) telmisartan is as effective as, and better tolerated than, the gold standard angiotensin-converting...

Science and Environment

Cardiovascular study underway

November 19, 2001 - 12:00am

The pharmaceutical company Boehringer Ingelheim has presented before the American Heart Association’s annual meeting its extensive cardiovascular trial program ONTARGET. The program will investigate the additional...

Science and Environment

Study centers in 40 countries involved in heart pr

September 17, 2001 - 12:00am

A total of 793 study centers in 40 countries have been recruited to enroll 28,400 patients over two years for the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) cardiovascular...

Science and Environment